LeeDCranmerMD

PubMed

• Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020.
  Ed Y Kim, Daniela Duarte-Bateman, Bonny Chau, Michael J Wagner, Vinod Ravi, Stephanie K Schaub, Jeremy Sharib, Harveshp Mogal, Min Park, Michaela Tsai, Anthony Tufaro,...> ;JAMA Network Open. 2024 Apr 1
• Phase II Trial ofSirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update.
  Andrew J Wagner, Vinod Ravi, Richard F Riedel, Kristen Ganjoo, Brian A Van Tine, Rashmi Chugh, Lee Cranmer, Erlinda M Gordon, Jason L Hornick, Heng Du, Li Ding, Anita ...> ;Journal of Clinical Oncology. 2024 May 1
• 6 citations
  Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial.
  Yongwoo David Seo, Hailing Lu, Graeme Black, Kimberly Smythe, Yuexin Yu, Cynthia Hsu, Juliana Ng, Pedro Hermida de Viveiros, E Houston Warren, Brett A Schroeder, Ryan ...> ;JAMA Oncology. 2023 Dec 1
• 1 citations
  Incidence, demographics, and survival of malignant hemangioendothelioma in the United States.
  Kelly G Paulson, Vinod Ravi, Brian P Rubin, Min Park, Elizabeth T Loggers, Lee D Cranmer, Michael J Wagner> ;Cancer Medicine. 2023 Jul 1
• 3 citations
  Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib.
  Cass G G Sunga, Michael S Higgins, Robert W Ricciotti, Yajuan J Liu, Lee D Cranmer> ;Cancer Reports. 2023 Mar 1
• 1 citations
  Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406).
  Lee D Cranmer, Yao Lu, Rachel S Heise, Karla V Ballman, Elizabeth T Loggers, Seth M Pollack, Michael J Wagner, Denise K Reinke, Patrick Schöffski, William D Tap> ;Clinical Cancer Research. 2023 Mar 14
• 2 citations
  Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: A real-world database study.
  Lee D Cranmer, Lisa M Hess, Tomoko Sugihara, Howard G Muntz> ;Cancer Reports. 2023 Jan 1
• 12 citations
  A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
  Michael J Wagner, Yuzheng Zhang, Lee D Cranmer, Elizabeth T Loggers, Graeme Black, Sabrina McDonnell, Shannon Maxwell, Rylee Johnson, Roxanne Moore, Pedro Hermida de V...> ;Clinical Cancer Research. 2022 Jun 1
• 11 citations
  Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
  Robin L Jones, Vinod Ravi, Andrew S Brohl, Sant Chawla, Kristen N Ganjoo, Antoine Italiano, Steven Attia, Melissa A Burgess, Katherine Thornton, Lee D Cranmer, Maggie ...> ;JAMA Oncology. 2022 May 1
• 61-year-old man with dyspnea and bilateral foot drop.
  Cranmer LD, Warrington KJ, Ytterberg SR> ;Mayo Clinic proceedings.
• 32 citations
  Rodent models of brain metastasis in melanoma
  Lee D. Cranmer, Katrina T. Trevor, Surekha Bandlamuri, Evan M. Hersh> ;Melanoma Research. 2005 Oct 1
• A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid ...
  Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA> ;Clinical cancer research : an official journal of the American Association for Cancer Research.
• 39 citations
  The role of the CTLA4 blockade in the treatment of malignant melanoma.
  Lee D. Cranmer, Evan M. Hersh> ;Cancer Investigation. 2007 Oct 1
• Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.
  Chalasani P, Shtivelband MI, Cranmer LD> ;Clinical advances in hematology & oncology : H&O.
• In-transit metastasis from melanoma presenting as lymphangiectasis: a case report.
  Shekhel T, Glick RM, Cranmer LD> ;Cutis.
• Whole-brain radiation therapy in melanoma: an open question.
  Cranmer LD, Jeter JM, Morgan SS, Hersh EM, Stea B> ;The Lancet. Oncology.
• 2 citations
  Melanoma’s Radioresistant Reputation Challenged
  Lee D. Cranmer> ;Oncology. 2010 Jun 1
• Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.
  Morgan SS, Cranmer LD> ;Current oncology reports.
• A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
  Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A> ;Journal of immunotherapy (Hagerstown, Md. : 1997).
• Ipilimumab granulomatous interstitial nephritis.
  Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD> ;American journal of therapeutics.
• 8 citations
  Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer
  John Sarantopoulos, Monica M. Mita, Michael J. Birrer, Lee D. Cranmer, Luis T. Campos, Xiaoping Zhang, Penelope Bristow, Hidekuni Kaito, Vincent Strout, Luis H. Camacho> ;Targeted Oncology. 2016 Jun 1
• Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases.
  Glazer ES, Bartels PH, Lian F, Kha ST, Morgan SS, da Silva VD, Yozwiak ML, Bartels HG, Cranmer LD, de Oliveira JK, Alberts DS, Warneke JA, Krouse RS> ;Melanoma research.
• Development and Validation of a Clinical Trial Accrual Predictive Regression Model at a Single NCI-Designated Comprehensive Cancer Center.
  Tate WR, Cranmer LD> ;Journal of the National Comprehensive Cancer Network : JNCCN.
• 133 citations
  Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
  Omid Hamid, Igor Puzanov, Reinhard Dummer, Jacob Schachter, Adil Daud, Dirk Schadendorf, Christian U. Blank, Lee D. Cranmer, Caroline Robert, Anna C. Pavlick, Rene Gon...> ;European Journal of Cancer. 2017 Nov 1
• Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
  Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, L...> ;Melanoma research.
• Join now to see all